These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19239418)

  • 1. Anti-aging activity of the Ink4/Arf locus.
    Matheu A; Maraver A; Collado M; Garcia-Cao I; Cañamero M; Borras C; Flores JM; Klatt P; Viña J; Serrano M
    Aging Cell; 2009 Apr; 8(2):152-61. PubMed ID: 19239418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed ageing through damage protection by the Arf/p53 pathway.
    Matheu A; Maraver A; Klatt P; Flores I; Garcia-Cao I; Borras C; Flores JM; Viña J; Blasco MA; Serrano M
    Nature; 2007 Jul; 448(7151):375-9. PubMed ID: 17637672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic mice.
    Fuster JJ; Molina-Sánchez P; Jovaní D; Vinué Á; Serrano M; Andrés V
    Atherosclerosis; 2012 Mar; 221(1):98-105. PubMed ID: 22226369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging.
    Matheu A; Pantoja C; Efeyan A; Criado LM; Martín-Caballero J; Flores JM; Klatt P; Serrano M
    Genes Dev; 2004 Nov; 18(22):2736-46. PubMed ID: 15520276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.
    Gilley J; Fried M
    Oncogene; 2001 Nov; 20(50):7447-52. PubMed ID: 11704876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging.
    González-Navarro H; Vinué Á; Sanz MJ; Delgado M; Pozo MA; Serrano M; Burks DJ; Andrés V
    Aging Cell; 2013 Feb; 12(1):102-11. PubMed ID: 23107464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-Dependent and -independent functions of the Arf tumor suppressor.
    Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
    Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ink4a/Arf links senescence and aging.
    Sharpless NE
    Exp Gerontol; 2004; 39(11-12):1751-9. PubMed ID: 15582292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased gene dosage of Ink4/Arf and p53 delays age-associated central nervous system functional decline.
    Carrasco-Garcia E; Arrizabalaga O; Serrano M; Lovell-Badge R; Matheu A
    Aging Cell; 2015 Aug; 14(4):710-4. PubMed ID: 25990896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Arf/p53 pathway in cancer and aging.
    Matheu A; Maraver A; Serrano M
    Cancer Res; 2008 Aug; 68(15):6031-4. PubMed ID: 18676821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency.
    Leder A; McMenamin J; Zhou F; Moran JL; Beier DR; Leder P
    Oncogene; 2008 Apr; 27(17):2456-65. PubMed ID: 17952114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulation of INK4/ARF in cancer and aging.
    Kim WY; Sharpless NE
    Cell; 2006 Oct; 127(2):265-75. PubMed ID: 17055429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Ink4/Arf locus is a barrier for iPS cell reprogramming.
    Li H; Collado M; Villasante A; Strati K; Ortega S; Cañamero M; Blasco MA; Serrano M
    Nature; 2009 Aug; 460(7259):1136-9. PubMed ID: 19668188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into aging obtained from p53 mutant mouse models.
    Dumble M; Gatza C; Tyner S; Venkatachalam S; Donehower LA
    Ann N Y Acad Sci; 2004 Jun; 1019():171-7. PubMed ID: 15247009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.
    Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
    Clin Cancer Res; 2005 Apr; 11(8):2991-7. PubMed ID: 15837753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
    den Besten W; Kuo ML; Tago K; Williams RT; Sherr CJ
    Isr Med Assoc J; 2006 Apr; 8(4):249-51. PubMed ID: 16671360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
    Williams RT; Sherr CJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ink4-Arf locus in cancer and aging.
    Sherr CJ
    Wiley Interdiscip Rev Dev Biol; 2012; 1(5):731-41. PubMed ID: 22960768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.
    Gonzalez S; Klatt P; Delgado S; Conde E; Lopez-Rios F; Sanchez-Cespedes M; Mendez J; Antequera F; Serrano M
    Nature; 2006 Mar; 440(7084):702-6. PubMed ID: 16572177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a.
    Krimpenfort P; Ijpenberg A; Song JY; van der Valk M; Nawijn M; Zevenhoven J; Berns A
    Nature; 2007 Aug; 448(7156):943-6. PubMed ID: 17713536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.